The FDA approved updated labeling for Talzenna plus Xtandi for HRR gene-mutated metastatic castration-resistant prostate cancer, based on the TALAPRO-2 trial results. The TALAPRO-2 trial showed a ...

Adding the poly (ADP-ribose) polymerase (PARP) inhibitor niraparib to abiraterone acetate plus prednisone delayed disease progression and postponed the onset of symptoms in patients with metastatic ...

Pfizer is eyeing an earlier use of its PARP inhibitor Talzenna after a positive phase 3 trial in metastatic hormone-sensitive prostate cancer (mHSPC). | After an FDA snub in a broader metastatic ...

Akeega reduced radiographic progression or death risk by 37% in mCSPC patients with HRR gene alterations. Significant reduction in symptomatic progression risk by 50% and a trend towards improved ...

An international study reports that the combination of two drugs could significantly retard the development of a dangerous form of prostate cancer in men who have specific mutations in DNA repair ...

A powerful new drug combination—niraparib added to standard prostate cancer therapy—has been shown to significantly delay disease progression in men with specific DNA repair gene mutations. In the ...

An FDA advisory committee on Wednesday unanimously voted against recommending approval of the PARP inhibitor talazoparib (Talzenna) plus enzalutamide (Xtandi) for all patients with metastatic ...